Søren Risom Kristensen

Aug 19, 2023 | onlinelibrary.wiley.com | Jeppe Thorlacius-Ussing |Nordic Bioscience A |Søren Risom Kristensen |Morten Asser Karsdal

INTRODUCTION Small cell lung cancer (SCLC) is a rapidly progressive form of cancer with a poor prognosis that accounts for approximately 15% of all lung cancer cases.1 Despite recent advances, such as promising outcomes from immunotherapy,2 treatment options for SCLC are still restricted and primarily involve chemotherapy drugs such as platinum agents (cisplatin or carboplatin) and topoisomerase inhibitors (etoposide or irinotecan).